Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience
Sci Rep. 2021 May 13;11(1):10171. doi: 10.1038/s41598-021-89562-0.ABSTRACTThere…
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Nat Commun. 2021 Feb 17;12(1):1078. doi: 10.1038/s41467-020-20496-3.ABSTRACTBreast…
Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types
Sci Transl Med. 2021 Feb 10;13(580):eabc4465. doi: 10.1126/scitranslmed.abc4465.ABSTRACTAmong…
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors
J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105.ABSTRACTGermline…
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x.…
Immune Cell Associations with Cancer Risk
iScience. 2020 Jul 24;23(7):101296. doi: 10.1016/j.isci.2020.101296.…
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
JAMA Oncol. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134.ABSTRACTIMPORTANCE:…
NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity
Oncogene. 2020 Jul;39(30):5252-5266. doi: 10.1038/s41388-020-1361-x.…
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
EMBO Mol Med. 2020 Jun 8;12(6):e11217. doi: 10.15252/emmm.201911217.…
Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells
J Clin Med. 2020 Jan 27;9(2):353. doi: 10.3390/jcm9020353.ABSTRACTTraditionally,…
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nat Genet. 2020 Jan;52(1):56-73. doi: 10.1038/s41588-019-0537-1.…
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
Cancer Res. 2020 Feb 1;80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840.…
